Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

TCR-NK: TCR engineered NK Cell Development Service for Tumor Recognition Enhancement

Online Inquiry

Background Services Workflow Advantages Case Show FAQs Contact Us

Are you currently facing long development cycles for cell therapies, difficulty in achieving specific tumor recognition, or challenges in NK cell persistence and efficacy? Creative Biolabs' TCR-NK cell development service helps you accelerate the development of highly effective, tumor-specific cell therapies and enhance NK cell tumor recognition and persistence through advanced gene engineering, high-throughput screening, and innovative NK cell expansion and modification techniques.

The Imperative for TCR-NK: Addressing Immunotherapy Challenges

The evolving cancer immunotherapy landscape faces challenges in precise tumor targeting and overcoming immunosuppression. CAR-T cell therapies, though successful in hematological malignancies, have limited efficacy and toxicities in solid tumors. Natural Killer (NK) cells offer a promising, safer alternative with inherent anti-tumor activity and lower risk of cytokine release syndrome and GvHD. However, native NK cells often lack sufficient specificity and persistence for effective solid tumor eradication. TCR-engineered NK (TCR-NK) cells address this critical unmet need by combining NK cell anti-tumor capabilities with the exquisite antigen specificity of T-cell receptors (TCRs). This engineering allows NK cells to recognize MHC-restricted tumor antigens, expanding their targeting repertoire and enhancing precision for safer, more effective cancer immunotherapies.

Fig.1 NK cell engineering strategies. (OA Literature) Fig.1 Various NK cell engineering strategies for enhanced functions.^1,3

TCR-NK: TCR-engineered NK Cell Development Service for Tumor Recognition Enhancement at Creative Biolabs

Creative Biolabs offers a comprehensive TCR-NK cell development service designed to empower your cancer immunotherapy research and development. Our service encompasses a streamlined workflow, from NK cell isolation and TCR gene transfer to functional validation and large-scale production, providing characterized cell lines and detailed data reports, typically within 12-20 weeks, all to enhance the precision and efficacy of your cell therapy projects with scientifically grounded solutions.

Workflow: From Concept to Preclinical Efficacy

Step 1

NK Cell Isolation and Expansion

We begin by isolating NK cells from your provided source material. These cells are then expanded using optimized protocols to ensure a sufficient number of high-purity NK cells for subsequent engineering. This step ensures a robust starting population for modification.

Step 2

TCR Gene Transfer

Utilizing advanced viral or non-viral gene transfer methods, we introduce the desired TCR alpha and beta chain genes into the expanded NK cells. Our expertise ensures efficient and stable integration of the TCR genes into the NK cell genome.

Step 3

TCR Expression Validation and Characterization

Following gene transfer, we meticulously validate the expression of the introduced TCRs on the surface of the NK cells using techniques such as flow cytometry. We also assess the viability and purity of the engineered cells. This step confirms successful engineering.

Step 4

Functional Assessment and Optimization

The engineered TCR-NK cells undergo rigorous in vitro functional assays. This includes cytotoxicity assays (e.g., co-culture with target tumor cells to measure killing efficiency), cytokine release assays, and proliferation studies. We optimize conditions to ensure maximal tumor recognition and effector function.

Step 5

Large-Scale Production and Quality Control

For projects requiring larger quantities, we scale up the production of the optimized TCR-NK cells under stringent quality control measures. Comprehensive testing is performed to ensure product consistency, sterility, and potency.

Our Service Highlights

Enhanced Tumor Specificity: Leveraging precise TCR antigen recognition, our service enables targeting of intracellular antigens presented on MHC molecules, which are inaccessible to CAR-based therapies.
Reduced Off-Target Effects: This precise targeting leads to improved safety profiles and minimized off-target interactions.
Allogeneic Potential: NK cells' inherent ability to kill without prior sensitization and lower propensity for GvHD make TCR-NK cells highly attractive for allogeneic (off-the-shelf) applications.
Broader Antigen Recognition: Compared to CARs, TCR-NK cells offer broader antigen recognition capabilities, expanding the range of treatable cancers, particularly solid tumors.
Accelerated Therapeutic Development: Our service harnesses these benefits to significantly accelerate your therapeutic development timeline.

Case Show

This study successfully demonstrated the efficacy of T-cell receptor (TCR) expression in NK cells. This TCR complex, when properly assembled, led to robust degranulation, IFNγ production, and target cell killing. The findings highlight the therapeutic potential of TCR-engineered NK cells.

Fig.2 Cytotoxicity of sorted genetically modified NK cells upon co-cultured with target cells. (OA Literature) Fig.2 The cytotoxic activity of engineered NK cell subsets against target cells.^2,4

FAQs

Q1: How does TCR-NK compare to CAR-NK or CAR-T cell therapies?

A1: TCR-NK cells offer distinct advantages, particularly in targeting intracellular antigens presented by MHC molecules, which CAR-based therapies cannot. While CAR-T cells have shown efficacy, TCR-NK cells leverage the innate safety profile of NK cells, potentially reducing risks like severe cytokine release syndrome and graft-versus-host disease, and offer potential for allogeneic "off-the-shelf" applications.

Q2: What is the typical turnaround time for a TCR-NK development project?

A2: The typical timeframe for our TCR-NK Cell Development Service ranges from 12 to 20 weeks. This duration can vary depending on the complexity of the target antigen, the specific TCR sequences involved, and the scale of engineered cell production required. We provide a detailed project timeline after initial consultation.

Q3: Can Creative Biolabs assist with regulatory aspects for clinical translation?

A3: While our primary service focuses on the development and characterization of TCR-NK cells, our team possesses extensive experience in preclinical development. We can provide data packages and guidance that support your regulatory submissions, and we are happy to connect you with our network of regulatory experts for comprehensive support.

Related Services

To further support your immunotherapy research and development, Creative Biolabs also offers a suite of established services to help engineer your NK cells for improved functions:

Work with Creative Biolabs

Creative Biolabs is your trusted partner in advancing cutting-edge cell therapies. Our TCR-NK Cell Development Service provides a robust, efficient, and highly specific solution for enhancing tumor recognition and accelerating your therapeutic breakthroughs. Leveraging our deep scientific expertise and state-of-the-art platforms, we are dedicated to delivering high-quality, functionally validated TCR-NK cells tailored to your unique project needs. If you want to know more for our TCR-NK development service, please contact us with your meaningful projects.

References

Page, Audrey et al. "Development of NK cell-based cancer immunotherapies through receptor engineering." Cellular & molecular immunology vol. 21,4 (2024): 315-331. DOI:10.1038/s41423-024-01145-x.
Rasul, Khder H et al. "Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells." Current issues in molecular biology vol. 44,9 3859-3871. 25 Aug. 2022, DOI:10.3390/cimb44090265
Distributed under Open Access License CC BY 4.0, without modification.
Distributed under Open Access License CC BY 4.0. The original image was modified by extracting and regrouping figure A and figure B, and the title was changed to "The cytotoxic activity of engineered NK cell subsets against target cells".

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.